FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

堆栈库

The Healer

Recoverybeginner
12
Share
肽类

2

平均每日mcg

0

级别

beginner

添加时间

May 7, 2026

概述

The Healer is a foundational recovery stack built on the two most well-researched tissue repair peptides in the field. Designed for beginners entering the world of peptide therapy, this straightforward two-peptide protocol delivers powerful regenerative signaling without the complexity of advanced multi-compound stacks. It represents the essential starting point for anyone seeking accelerated recovery from injuries, chronic pain conditions, or general tissue wear. BPC-157, administered at 250mcg subcutaneously once daily, is a body protection compound originally isolated from human gastric juice. This 15-amino-acid peptide has accumulated an impressive body of preclinical research demonstrating its ability to heal virtually every tissue type studied, including muscle, tendon, ligament, bone, intestinal lining, and neural tissue. It works through multiple pathways: promoting angiogenesis via VEGF upregulation, accelerating fibroblast migration to injury sites, modulating nitric oxide systems for improved blood flow, and protecting cells from oxidative damage. Daily subcutaneous administration near an injury site provides consistent local tissue concentrations for optimal repair signaling. TB-500, dosed at 2.5mg subcutaneously twice weekly, is a synthetic version of the active region of Thymosin Beta-4, a naturally occurring 43-amino-acid protein involved in tissue repair throughout the body. TB-500 promotes healing by upregulating actin polymerization, which enhances cell migration and proliferation at injury sites. Unlike BPC-157, TB-500 distributes systemically regardless of injection location, making it effective for diffuse or hard-to-reach injuries. It also exhibits significant anti-inflammatory properties and has been shown to reduce scar tissue formation, promoting more functional tissue restoration. The synergy between these two peptides is well-established in the peptide therapy community. BPC-157 provides targeted local repair amplification while TB-500 creates a systemic pro-healing environment. Together they address injuries from multiple angles: inflammation reduction, blood vessel formation, cell migration, and structural protein synthesis. This stack is ideal for athletes recovering from training injuries, individuals with chronic musculoskeletal pain, or anyone experiencing slow healing. The protocol runs for 4-8 weeks depending on injury severity. No complex cycling is required, making it the perfect entry point for peptide therapy newcomers. Subcutaneous injection technique is simple to learn and well-tolerated.

给药方案

BPC-157

Every day· subcutaneous

了解更多关于BPC-157 →

250mcg

每剂

TB-500

Twice per week· subcutaneous

了解更多关于TB-500 →

2.5mg

每剂

目标与证据

证据等级:community

Comments

Sign in to join the discussion

免责声明: 此堆栈由社区提交,仅供研究用途。Peptide Contacts不对提交的堆栈的安全性或有效性进行验证。使用任何肽类协议前,请务必咨询合格的医疗专业人员。